Company intelligence / Profile preview

Protembis

Ownership: Private
Development stage: Phase 3

Overview

Protembis has developed the ProtEmbo Cerebral Protection System, an intra-aortic filter device designed to protect the entire brain from embolic material released during TAVR. Clinical studies have shown that up to 94% of patients treated with ProtEmbo are free from clinically meaningful new brain lesions (>350mm³). The ongoing pivotal PROTEMBO IDE trial aims to demonstrate superiority over current standards and no-protection controls. No ProtEmbo-related adverse events have been reported in trials so far.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

ProtEmbo Cerebral Protection System

Phase 3

Indications: Brain protection during TAVR procedures

Partnerships

No major pharmaceutical or biotech partnerships disclosed

Beyond the preview

Go deeper on Protembis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protembis.

Explore the full profile